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Formalin-fixed frontal cortex samples from two controls and five AD individuals (Braak VI and Thal 5) were obtained from the Brain Bank GIe NeuroCeB with legal consent. Brain samples were cut at a thickness of 500 μm with a vibratome and were processed by the CLArITY technique [5] . embedded in an acrylamide hydrogel constituted of 4 % paraformaldehyde (pFA), 4 % acrylamide, 0.25 % temperature-triggering initiator VA-044, pBs, the tissues were passively clarified at 37 °C for 2 weeks in the clearing solution (200 mM boric acid, 4 % w/v sDs, pH 8.5). The blocks were immunostained with a rabbit polyclonal anti-tau B19 antibody [3] and a mouse monoclonal anti-Aβ 4G8 antibody (Covance). Alexa Fluor ® 488 goat anti-rabbit and Alexa Fluor ® 568 goat anti-mouse antibodies (Life technologies) were used as secondary antibodies. For Aβ and neurofilament double immunohistochemistry, the tissues were first incubated with mouse monoclonal anti-neurofilament antibody (M0762 Dako) and then with Alexa Fluor ® 568 goat anti-mouse antibody. After a blocking stage (10 % normal mouse serum), the tissues were incubated with biotin-labelled 4G8 anti-Aβ antibody (Covance), revealed with DyLight 488-labelled streptavidin (KpL, eurobio, France). Triple staining (Aβ, tau and neurofilament) was also performed: the block was incubated with anti-tau B19 and anti-neurofilament M0762 antibodies revealed with the secondary Alexa Fluor ® 488 goat antirabbit and Alexa Fluor ® 568 goat anti-mouse antibodies. The third antibody was a biotin-labelled anti-Aβ 4G8 antibody (Covance) revealed with streptavidin-Alexa 405 (Life technology). The mounting protocol was modified from the original method: we added a fixation step (4 % pFA in pBs for 15 min) at the end of the procedure to improve Alzheimer's disease (AD) is characterized by extracellular deposits of amyloid β (Aβ) peptide and intracellular tau aggregates. examination of these lesions in post-mortem brain tissue routinely provides a two-dimensional picture of the pathology with a limited depth of field. several tissue-clearing protocols have been recently published [1, 4-6, 8, 10, 11, 16] . We compared the quality of immunostaining on post-mortem human brain tissues using several clearing techniques including CLArITY [4, 5] , scale [8] , seeDB [9] , and 3DIsCO [6] . results were best with CLArITY. In that method, acrylamide hydrogel links the protein of the tissue and maintains its structure. removing the lipids makes the block transparent and facilitates the stability of the immunostaining, and an incubation step (0.2 M glycine for 15 min) to quench autofluorescence. We used scaleA2 solution as mounting medium [8] , instead of 80 % glycerol or FocusClear described in the original method [5] . scaleA2 increased the transparency of the tissue compared to 80 % glycerol, lowered the cost of the experiment compared to FocusClear and shortened incubation time (overnight compared to 2 days). The immunolabellings were analysed with an upright confocal microscope (Olympus Fluoview Fv1000). The Z-stack images were re-constructed using Imaris software (Bitplane).
The volume of the "clarified" block was increased by approximately 40 % after passive removal of the lipids. While 80 % glycerol or FocusClear restored the volume in the original CLArITY technique, scaleA2 further increased it but kept the morphological quality of the technique. The combination of CLArITY and scaleA2 is not appropriate for stereological measures because of the volume expansion. Despite the increase in volume, the axons (shown by neurofilament immunostaining) remained continuous (supplementary videos 2-3). The clarified tissues were fully transparent. The video, obtained with confocal microscopy, provides a 3-D view of the lesions revealed by Aβ and tau immunohistochemistry (video 1). Amyloid deposits appeared to have diverse 3-D structure in AD brains: some deposits were dense and focal; some diffuse deposits appeared hollow (video 1). Accumulation of Aβ was regularly spaced in clumps throughout the cortex (video 1). Tau accumulated in segmented and discontinuous neuritic processes. Many dystrophic neurites were associated with dense, focal, presumably "mature" Aβ focal deposits [2] .
plaque-induced distorted neurites have been previously reported by in vivo observation in AD transgenic animal [7, 12, 13, 15] and in the affected areas of post-mortem human AD brains [10, 14] . Our video of Aβ and neurofilament double immunostaining showed the persistence of a large number of axons, one of them (traced in yellow) deflected by the focal deposits (video 2).
Finally, a triple immunostaining for Aβ (blue), tau (green) and neurofilament (red) showed that the tangle bearing neuron that we identified had no visible axonal projection (video 3). The region of the Aβ focal deposit contained few axons. The Aβ immunoreactivity (revealed with an avidin biotin amplification step) was excellent through the whole thickness of the block. Neurofilament and tau immunoreactivities (revealed with no amplification step) were stronger in a 150-µm-thick layer at the top of the block. The transparency of the block was, however, homogeneous. The 150-µm-thick layer of high immunoreactivity was detected at the top and at the bottom of the block: it was not related to a defect in the penetration of the laser beam during the imaging process but to better antibody penetration near the surface. Longer incubation time, higher concentration of detergent in the buffer and various amplification systems will be tested in the future to improve the homogeneity of the signal throughout the thickness of the sample.
These first results uncover the 3-D architecture of AD lesions and demonstrate the utility of the CLArITY technique in studying the distribution of AD pathology in 3-D, even in post-mortem human tissue.
